Results 1 to 10 of about 1,812 (112)
Post-finasteride syndrome, [PDF]
Anais Brasileiros de Dermatologia, 2020 Finasteride is a 5α-reductase enzyme inhibitor that has been approved for the treatment of male androgenic alopecia since 1997. Over time, it has been considered a safe and well-tolerated drug with rare and reversible side effects.
Ana Francisca Junqueira Ribeiro Pereira +1 more
doaj +8 more sources
Post-finasteride syndrome: An emerging clinical problem [PDF]
Neurobiology of Stress, 2020 The presence of side effects during pharmacological treatment is unfortunately a quite common problem. In this review, we focused our attention on adverse events related to 5 alpha-reductase (5α-R) inhibitors (i.e., finasteride and dutasteride), approved
Silvia Diviccaro +2 more
doaj +6 more sources
Case report: a study of the clinical characteristics and genetic variants of post-finasteride syndrome patients [PDF]
Translational Andrology and Urology, 2022 Finasteride is widely used in the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia (AGA). Post-finasteride syndrome (PFS) is a spectrum of persistent symptoms reported by some patients after treatment with finasteride for androgenetic alopecia.
Hongjun Li
exaly +4 more sources
A Comment on the Post-Finasteride Syndrome. [PDF]
Int J Trichology, 2018 The post-Finasteride syndrome (PFS) has been claimed to occur in men who have taken oral finasteride to treat hair loss or benign prostatic hyperplasia. While the incidence of persistent sexual, mental, and physical side effects despite quitting finasteride is unknown, and the condition is not recognized by the scientific community, individuals who ...
Rezende HD, Dias MFRG, Trüeb RM.
europepmc +4 more sources
Post-finasteride syndrome: our current knowledge
Вестник урологии, 2020 5-α reductase inhibitors are effective and commonly used medications for the treatment of benign prostatic hyperplasia. However, there are some questions about the safety of such medications.
A. A. Galushkin +2 more
doaj +3 more sources
Post-finasteride syndrome: a surmountable challenge for clinicians [PDF]
Fertility and Sterility, 2020 Post-finasteride syndrome (PFS) is a constellation of serious adverse side effects manifested in clinical symptoms that develop and persist in patients during and/or after discontinuing finasteride treatment in men with pattern hair loss (androgenetic alopecia) or benign prostatic hyperplasia.
Abdulmaged Traish
exaly +3 more sources
Atypical post-finasteride syndrome: A pharmacological riddle.
Indian J Pharmacol, 2016 Finasteride and dutasteride are commonly used 5-alpha reductase inhibitors. While finasteride is a selective inhibitor of 5-alpha reductase Type II, dutasteride inhibits 5- alpha reductase Type I and II. The United States Food and Drug Administration approved the use of finasteride for benign prostatic hypertrophy (BPH) as well as androgenic alopecia ...
Gupta AK, Sharma N, Shukla P.
europepmc +4 more sources
Differential Gene Expression in Post-Finasteride Syndrome Patients
Journal of Sexual Medicine, 2021 ABSTRACTBackgroundAn organic etiology underpinning post-finasteride syndrome, a constellation of persistent sexual, neuropsychiatric, and somatic symptoms reported by men exposed to 5-alpha-reductase inhibitors (5ARIs), is debated. Persistent changes in neurosteroid levels or androgen receptor expression have been implicated.AimTo determine whether ...
, Alexander Pastuszak
exaly +3 more sources
Post-finasteride syndrome – does it really exist?
Aging Male, 2019 Inhibitors of 5α-steroid reductase are drugs used to treat androgen-dependent conditions including prostate diseases and androgenic alopecia. Finasteride was the first on the market and is currently the most widely used inhibitor. Dutasteride was the second inhibitor to be approved and has a similar safety profile.
Michal Rabijewski +2 more
exaly +3 more sources
Post-Finasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psychogenic Illness? [PDF]
Skin Appendage Disord, 2019 Post-finasteride syndrome (PFS) has been claimed to occur in men who have taken oral finasteride to treat either hair loss or benign prostatic hyperplasia, independent of age, dosage, or indication. By definition, the condition is characterized by sexual dysfunction, somatic symptoms, and psychological disorders that persist after cessation of ...
Trüeb RM +3 more
europepmc +4 more sources